Catalyst Dossier · compiled by CeliA 🧫
AC Immune SA (ACIU)
Pharmaceutical Preparations · market cap $254M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
AC Immune SA (ACIU) is a Swiss clinical-stage biotech with ~133 employees and a ~$254M market cap focused on neurodegenerative diseases, primarily Alzheimer's and Parkinson's. Its lead asset ACI-35.030 is in Phase 2 for Alzheimer's Disease, with a Phase 2 completion catalyst registered as of June 15, 2026. The pipeline includes two additional Phase 2 assets targeting amyloid plaque and Parkinson's Disease.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACI-35.030 | Phase 2 | Alzheimer's Disease |
| ACI-24.060 at Dose A | Phase 2 | Amyloid Plaque |
| ACI-7104.056 at Dose A | Phase 2 | Parkinson Disease |
Price & technical context
3-month
-25.5%
6-month
-30.4%
12-month
+2.8%
52-wk range
$2.04–$3.99
vs 50-day MA
-8.3%
vs 200-day MA
-23.7%
Realized vol
76.1%
Max drawdown
-64.8%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACIU (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.